PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Disease Reportsvon hippel-lindau disease
MeSH D006623 - von hippel-lindau disease
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D020752:Neurocutaneous syndromes
0 Companies
0 Drugs
Success rate
D000798:Angiomatosis
0 Companies
0 Drugs
Success rate
D000072661:Ciliopathies
0 Companies
0 Drugs
Success rate
D006623: 
Von hippel-lindau disease
$
Success rate
Events Timeline
Loading
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
Merck & CoBelzutifan Welireg 2034-09-05 2021-08-13 $421 M Q4/23-Q3/24 
Clinical Trials
Historical Success Rate
Phase 1
50%
3/6
Phase 2
0%
0/9
Phase 3
100%
1/1
Approved: 1Overall Success rate: 0%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Merck & Co
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use